Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
2010-023809-36Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Mar 2012
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cytarabine, daunorubicin, idarubicin, fludarabine, etoposide and 1 more in acute myeloid leukemia (AML), sponsored by GIMEMA. Primary endpoint: Overall survival at 24 months. Started Mar 2012; status: completed.
02
Drugs
cytarabinedaunorubicinidarubicinfludarabineetoposide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2010-023809-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023809-36.